{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:04:44Z","timestamp":1785769484612,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82400832"],"award-info":[{"award-number":["No. 82400832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82170737, 82370707"],"award-info":[{"award-number":["No. 82170737, 82370707"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Guangdong Province High-Level Hospital Construction Project","award":["No. DFJHBF202101"],"award-info":[{"award-number":["No. DFJHBF202101"]}]},{"name":"the National Key Research and Development Project of China \u2014\u2014 Strategy study on lupus nephritis diagnosis and treatment","award":["2021YFC2501302"],"award-info":[{"award-number":["2021YFC2501302"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02503-y","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:16:32Z","timestamp":1744258592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of remnant cholesterol on adverse renal outcomes in lupus nephritis"],"prefix":"10.1186","volume":"24","author":[{"given":"Xiaolei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haishan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5250-6239","authenticated-orcid":false,"given":"Ruihan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2503_CR1","doi-asserted-by":"crossref","unstructured":"Parodis I, Depascale R, Doria A, Anders H-J. When should targeted therapies be used in the treatment of lupus nephritis: early in the disease course or in refractory patients? Autoimmun Rev. 2023:103418.","DOI":"10.1016\/j.autrev.2023.103418"},{"key":"2503_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/CM9.0000000000002959","volume":"137","author":"X Jia","year":"2024","unstructured":"Jia X, Lu Y, Zheng X, Tang R, Chen W. Targeted therapies for lupus nephritis: current perspectives and futur e directions. Chin Med J. 2024;137:34.","journal-title":"Chin Med J"},{"key":"2503_CR3","doi-asserted-by":"publisher","first-page":"102871","DOI":"10.1016\/j.jaut.2022.102871","volume":"132","author":"C Yu","year":"2022","unstructured":"Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022;132:102871.","journal-title":"J Autoimmun"},{"key":"2503_CR4","doi-asserted-by":"crossref","unstructured":"Ma SSSF, Nm S, Ba AB. Frequency of dyslipidemia in patients with lupus nephritis. Pakistan J Med Sci. 2017;33.","DOI":"10.12669\/pjms.332.12410"},{"key":"2503_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.semarthrit.2015.10.010","volume":"45","author":"K Tselios","year":"2016","unstructured":"Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45:604\u201310.","journal-title":"Semin Arthritis Rheum"},{"key":"2503_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrneph.2009.184","volume":"5","author":"XZ Ruan","year":"2009","unstructured":"Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713\u201321.","journal-title":"Nat Rev Nephrol"},{"key":"2503_CR7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s10067-023-06539-2","volume":"42","author":"S Huang","year":"2023","unstructured":"Huang S, Zhang Z, Cui Y, Yao G, Ma X, Zhang H. Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosus. Clin Rheumatol. 2023;42:1565\u201372.","journal-title":"Clin Rheumatol"},{"key":"2503_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.scib.2023.12.035","volume":"69","author":"Associations of remnant","year":"2024","unstructured":"Associations of remnant. Cholesterol with cardiovascular and cancer mortality in a nationwide cohort. Sci Bull. 2024;69:526\u201334.","journal-title":"Sci Bull"},{"key":"2503_CR9","unstructured":"O C, Aj XPIS, E A, \u00c1 R, M\u00e1 H. M-G, D C, J S-S, RE. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76."},{"key":"2503_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12944-024-02033-z","volume":"23","author":"Y Yan","year":"2024","unstructured":"Yan Y, La R, Jiang M, Xu W, Jiang D, Wang S, Huang L, Wu Q. The association between remnant cholesterol and rheumatoid arthritis: insights from a large population study. Lipids Health Dis. 2024;23:38.","journal-title":"Lipids Health Dis"},{"key":"2503_CR11","unstructured":"O HFSS, S HSK, M NTS. Y, HO, DF, KK. Prognostic value of remnant-like lipoprotein particle levels in Patien Ts with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol. 2004;43."},{"key":"2503_CR12","doi-asserted-by":"publisher","first-page":"111639","DOI":"10.1016\/j.diabres.2024.111639","volume":"210","author":"SY Jang","year":"2024","unstructured":"Jang SY, Kang M, Song E, Jang A, Choi KM, Baik SH, Yoo HJ. Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: a nationwide population-based study. Diabetes Res Clin Pract. 2024;210:111639.","journal-title":"Diabetes Res Clin Pract"},{"key":"2503_CR13","doi-asserted-by":"crossref","unstructured":"LY, PY. Relationship between remnant cholesterol and risk of kidney stones in U.S. Adults: A 2007\u20132016 NHANES analysis. Ann Med. 2024;56.","DOI":"10.1080\/07853890.2024.2319749"},{"key":"2503_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12888-023-04770-4","volume":"23","author":"Y Wang","year":"2023","unstructured":"Wang Y, Shen R. Association of remnant cholesterol with depression among US adults. BMC Psychiatry. 2023;23:259.","journal-title":"BMC Psychiatry"},{"key":"2503_CR15","doi-asserted-by":"crossref","unstructured":"Yuan Y, Hu X, Zhang S, Wang W, Yu B, Zhou Y, Ou Y, Dong H. Remnant cholesterol, preinflammatory state and chronic kidney disease: association and mediation analyses. Ren Fail. 2024;46(2):2361094.","DOI":"10.1080\/0886022X.2024.2361094"},{"key":"2503_CR16","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and is chemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298\u2013309.","journal-title":"Circulation"},{"key":"2503_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"2503_CR18","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1038\/s41467-024-46686-x","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhuang Z, Li Y, Xiao W, Song Z, Huang N, Wang W, Dong X, Jia J, Clarke R, Huang T. Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. Nat Commun. 2024;15:2451.","journal-title":"Nat Commun"},{"key":"2503_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"2503_CR20","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.4103\/0366-6999.232809","volume":"131","author":"D-N Chen","year":"2018","unstructured":"Chen D-N, Fan L, Wu Y-X, Zhou Q, Chen W, Yu X-Q. A predictive model for estimation risk of proliferative lupus nephritis. Chin Med J. 2018;131:1275\u201381.","journal-title":"Chin Med J"},{"key":"2503_CR21","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3899\/jrheum.191064","volume":"47","author":"K Tselios","year":"2020","unstructured":"Tselios K, Gladman DD, Su J, Urowitz MB. Advanced chronic kidney disease in lupus nephritis: is dialysis inevit able? J Rhuematol. 2020;47:1366\u201373.","journal-title":"J Rhuematol"},{"key":"2503_CR22","doi-asserted-by":"crossref","unstructured":"Lichtnekert J, Anders H-J. Lupus nephritis-related chronic kidney disease. Nat Rev Rheumatol. 2025;21(1):63.","DOI":"10.1038\/s41584-024-01203-8"},{"key":"2503_CR23","doi-asserted-by":"crossref","unstructured":"Liu JA-O, Song WA-O, Cui DA-O. Relationship between blood lipid profiles and risk of lupus nephritis in children. Int J Clin Pract. 2022;26.","DOI":"10.1155\/2022\/6130774"},{"key":"2503_CR24","doi-asserted-by":"crossref","unstructured":"Feng H, Lu Q, Liu Y, Shi M, Lian H, Ni L, Wu X. Risk factors of disease activity and renal damage in patients with systemic lupus erythematosus. Int Urol Nephrol. 2024;56(12):3845\u201355.","DOI":"10.1007\/s11255-024-04105-6"},{"key":"2503_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12944-017-0622-3","volume":"16","author":"P Yin","year":"2017","unstructured":"Yin P, Zhou Y, Li B, Hong L, Chen W, Yu X. Effect of low and high HDL-C levels on the prognosis of lupus nephriti s patients: a prospective cohort study. Lipids Health Dis. 2017;16:232.","journal-title":"Lipids Health Dis"},{"key":"2503_CR26","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/eurheartj\/ehad298","volume":"44","author":"BN Wadstr\u00f6m","year":"2023","unstructured":"Wadstr\u00f6m BN, Wulff AB, Pedersen KM, Nordestgaard BG. Remnant cholesterol in the era of intensive lipid-lowering therapies. Eur Heart J. 2023;44:3483.","journal-title":"Eur Heart J"},{"key":"2503_CR27","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1093\/eurheartj\/ehac822","volume":"44","author":"BN Wadstr\u00f6m","year":"2023","unstructured":"Wadstr\u00f6m BN, Pedersen KM, Wulff AB, Nordestgaard BG. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur Heart J. 2023;44:1432\u201345.","journal-title":"Eur Heart J"},{"key":"2503_CR28","doi-asserted-by":"publisher","first-page":"108585","DOI":"10.1016\/j.jdiacomp.2023.108585","volume":"37","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Zhou X, Ji L. Association between remnant cholesterol level and severity of chronic kidney disease in patients with type 2 diabetes. J Diabetes Complicat. 2023;37:108585.","journal-title":"J Diabetes Complicat"},{"key":"2503_CR29","doi-asserted-by":"publisher","first-page":"1331603","DOI":"10.3389\/fendo.2024.1331603","volume":"15","author":"Q Li","year":"2024","unstructured":"Li Q, Wang T, Shao X, Fan X, Lin Y, Cui Z, Liu H, Zhou S, Yu P. Association of remnant cholesterol with renal function and its progression in patients with type 2 diabetes related chronic kidney disease. Front Endocrinol. 2024;15:1331603.","journal-title":"Front Endocrinol"},{"key":"2503_CR30","doi-asserted-by":"crossref","unstructured":"Zhao Y, Liu K, Zou Y, Wu Y, Yang J, Xiao X, Ju X, Yang Q, Lang Y, Liu F. Remnant cholesterol and the risk of diabetic nephropathy progression to end-stage kidney disease in patients with type 2 diabetes mellitus: A longitudinal cohort study. Endocrine. 2024;86(3):994\u20131002.","DOI":"10.1007\/s12020-024-03948-4"},{"key":"2503_CR31","doi-asserted-by":"crossref","unstructured":"Yuan T, Ding C, Xie Y, Zhou X, Xie C, Wang T, Yu C, Zhou W, Zhu L, Bao H, Cheng X. Association between remnant cholesterol and chronic kidney disease in Chinese hypertensive patients. Front Endocrinol. 2023;14.","DOI":"10.3389\/fendo.2023.1189574"},{"key":"2503_CR32","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00592-021-01765-z","volume":"58","author":"P Yan","year":"2021","unstructured":"Yan P, Xu Y, Miao Y, Bai X, Wu Y, Tang Q, Zhang Z, Yang J, Wan Q. Association of remnant cholesterol with chronic kidney disease in midd le-aged and elderly Chinese: a population-based study. Acta Diabetol. 2021;58:1615\u201325.","journal-title":"Acta Diabetol"},{"key":"2503_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12020-022-03012-z","volume":"76","author":"Q Zhai","year":"2022","unstructured":"Zhai Q, Dou J, Wen J, Wang M, Zuo Y, Su X, Zhang Y, Gaisano H, Mu Y, He Y. Association between changes in lipid indexes and early progression of kidney dysfunction in participants with normal estimated glomerular filtration rate: a prospective cohort study. Endocrine. 2022;76:312\u201323.","journal-title":"Endocrine"},{"key":"2503_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12944-024-02050-y","volume":"23","author":"HN Jung","year":"2024","unstructured":"Jung HN, Huh JH, Roh E, Han K-D, Kang JG, Lee SJ, Ihm S-H. High remnant-cholesterol levels increase the risk for end-stage renal disease: a nationwide, population-based, cohort study. Lipids Health Dis. 2024;23:165.","journal-title":"Lipids Health Dis"},{"key":"2503_CR35","doi-asserted-by":"crossref","unstructured":"X H. R Z, X D, K L, D S: Association of remnant cholesterol with decreased kidney function or a lbuminuria: a population-based study in the U.S. Lipids Health Dis. 2024;23.","DOI":"10.1186\/s12944-023-01995-w"},{"key":"2503_CR36","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/rheumatology\/keac407","volume":"62","author":"MF Zavala-Miranda","year":"2023","unstructured":"Zavala-Miranda MF, Perez-Arias AA, M\u00e1rquez-Macedo SE, Comunidad-Bonilla RA, Romero-Diaz J, Morales-Buenrostro LE, Mej\u00eda-Vilet JM. Characteristics and outcomes of a Hispanic lupus nephritis cohort from mexico. Rheumatology (Oxford). 2023;62:1136\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"2503_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5114\/ceji.2014.43730","volume":"39","author":"M Sui","year":"2014","unstructured":"Sui M, Jia X, Yu C, Guo X, Liu X, Ji Y, Mu S, Wu H, Xie R. Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: a prospective study. Central-European J Immunol. 2014;39:243\u201352.","journal-title":"Central-European J Immunol"},{"key":"2503_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1177\/0961203312443421","volume":"21","author":"VH Sato","year":"2012","unstructured":"Sato VH, Marques IDB, Goldenstein PT, Carmo LPF, Jorge LB, Titan SMO, Barros RT, Woronik V. Lupus nephritis is more severe in children and adolescents than in older adults. Lupus. 2012;21:978\u201383.","journal-title":"Lupus"},{"key":"2503_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/0961203315606985","volume":"25","author":"JM Mej\u00eda-Vilet","year":"2016","unstructured":"Mej\u00eda-Vilet JM, C\u00f3rdova-S\u00e1nchez BM, Arreola-Guerra JM, Morales-Buenrostro LE, Uribe-Uribe NO, Correa-Rotter R. Renal flare prediction and prognosis in lupus nephritis Hispanic patients. Lupus. 2016;25:315\u201324.","journal-title":"Lupus"},{"key":"2503_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1053\/j.ajkd.2016.07.026","volume":"68","author":"F Ward","year":"2016","unstructured":"Ward F, Bargman JM. Membranous lupus nephritis: the same, but different. Am J Kidney Dis. 2016;68:954\u201366.","journal-title":"Am J Kidney Dis"},{"key":"2503_CR41","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1093\/rheumatology\/keab126","volume":"60","author":"MSF Lu\u00eds","year":"2021","unstructured":"Lu\u00eds MSF, Bultink IEM, da Silva JAP, Voskuyl AE, In\u00eas LS. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study. Rheumatology (Oxford). 2021;60:5134\u201341.","journal-title":"Rheumatology (Oxford)"},{"key":"2503_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cca.2018.09.009","volume":"490","author":"M D\u00edaz-Ruiz","year":"2019","unstructured":"D\u00edaz-Ruiz M, Mart\u00ednez-Triguero ML, L\u00f3pez-Ruiz A, Fern\u00e1ndez-de la Cruz F, Ba\u00f1uls C, Hern\u00e1ndez-Mijares A. Metabolic disorders and inflammation are associated with familial comb ined hyperlipemia. Clin Chim Acta. 2019;490:194\u20139.","journal-title":"Clin Chim Acta"},{"key":"2503_CR43","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1093\/rheumatology\/keae226","volume":"63","author":"Y-S Sun","year":"2024","unstructured":"Sun Y-S, Huang D-F, Chang F-P, Chen W-S, Liao H-T, Chen M-H, Tsai H-C, Tsai M-T, Tsai C-Y, Lai C-C, Yang C-Y. Interstitial fibrosis increases the risk of end-stage kidney disease in patients with lupus nephritis. Rheumatology (Oxford). 2024;63:2467\u201372.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02503-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02503-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:16:39Z","timestamp":1744258599000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02503-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2503"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02503-y","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and approved by the Human Ethics Committee of Sun Yat-sen University (No. 2016\u2009\u2212\u2009215). Informed consent waivers from 2000 to 2016 were approved due to the retrospective nature of the study. Patients enrolled between 2017 and 2020 all signed written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}